GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Claritev Corp (NYSE:CTEV) » Definitions » Intrinsic Value: Projected FCF

CTEV (Claritev) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 01, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Claritev Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-06-01), Claritev's Intrinsic Value: Projected FCF is $0.00. The stock price of Claritev is $38.45. Therefore, Claritev's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Claritev's Intrinsic Value: Projected FCF or its related term are showing as below:

CTEV's Price-to-Projected-FCF is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.115
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Claritev Intrinsic Value: Projected FCF Historical Data

The historical data trend for Claritev's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Claritev Intrinsic Value: Projected FCF Chart

Claritev Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Claritev Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Claritev's Intrinsic Value: Projected FCF

For the Health Information Services subindustry, Claritev's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Claritev's Price-to-Projected-FCF Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Claritev's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Claritev's Price-to-Projected-FCF falls into.


;
;

Claritev Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Claritev  (NYSE:CTEV) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Claritev's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=38.45/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Claritev Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Claritev's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Claritev Business Description

Traded in Other Exchanges
N/A
Address
7900 Tysons One Place, Suite 400, McLean, VA, USA, 22102
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
Executives
Michael Kim officer: See Remarks POLARIS PARENT CORP, 115 FIFTH AVENUE, NEW YORK NY 10003
Anthony Jr Colaluca director MULTIPLAN CORPORATION, 115 FIFTH AVENUE, NEW YORK NY 10003
John Michael Prince director 115 FIFTH AVE., NEW YORK NY 10003
Nutter Carol officer: SVP, Chief People Officer 115 FIFTH AVE., NEW YORK NY 10003
Mark Tabak director, officer: Chief Executive Officer 115 FIFTH AVENUE, NEW YORK NY 10003
Michael K. Attal director 425 PARK AVENUE, 30TH FLOOR, NEW YORK NY 10022
James M Head officer: EVP & Chief Financial Officer 3001 COLORADO BLVD, DENTON TX 76210
Julie D Klapstein director 1239 FRUIT COVE ROAD NORTH, JACKSONVILLE FL 32259
C Martin Harris director
H&f Corporate Investors Viii, Ltd. 10 percent owner 415 MISSION STREET, SUITE 5700, SAN FRANCISCO CA 94105
Music Investments Gp, Llc 10 percent owner C/O HELLMAN & FRIEDMAN, ONE MARTIME PLAZA, 12TH FLOOR, SAN FRANCISCO CA 94111
Music Investments, L.p. 10 percent owner C/O HELLMAN & FRIEDMAN, ONE MARTIME PLAZA, 12TH FLOOR, SAN FRANCISCO CA 94111
Glenn R August director C/O OHA - 1114 AVENUE OF THE AMERICAS, 27TH FLOOR, NEW YORK NY 10036
Paul Galant officer: President, New Markets 88 WEST PLUMERIA DRIVE, SAN JOSE CA 95134
Michael Stuart Klein director, 10 percent owner, officer: Chief Executive Officer C/O DAVIS POLK & WARDWELL, 450 LEXINGTON AVENUE, NEW YORK NY 10017